Synergic actions of botulinum neurotoxin A and oxaliplatin on colorectal tumour cell death through the upregulation of TRPM2 channel-mediated oxidative stress
In conclusion, by increasing the susceptibility of HT29 tumour cells to oxidative stress and apoptosis, the combined administration of BoNT and OXA via the targeting of TRPM2 may offer a different approach to kill the tumour cells.PMID:38350599 | DOI:10.1111/1440-1681.13844 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 13, 2024 Category: Cancer & Oncology Authors: S ıdıka Demir İpek Duman Mustafa Naz ıroğlu Source Type: research
Clinicopathological characterisation of < em > MTAP < /em > alterations in gastrointestinal cancers
CONCLUSIONS: MTAP alterations are found in 5%-10% of GI cancers, most frequently biliopancreatic and gastro-oesophageal. MTAP loss is the most common alteration, identified almost exclusively in MSS, CDKN2A/B loss, upper-GI cancers. Other MTAP alterations were found in colorectal cancer, but unlikely to cause protein loss and drug susceptibility.PMID:38350716 | DOI:10.1136/jcp-2023-209341 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 13, 2024 Category: Cancer & Oncology Authors: Gianluca Mauri Giorgio Patelli Laura Roazzi Emanuele Valtorta Alessio Amatu Giovanna Marrapese Erica Bonazzina Federica Tosi Katia Bencardino Gabriele Ciarlo Elisa Mariella Silvia Marsoni Alberto Bardelli Emanuela Bonoldi Andrea Sartore-Bianchi Salvatore Source Type: research
RAS/RAF co-mutation and ERBB2 copy number modulates HER2 heterogeneity and responsiveness to HER2-directed therapy in colorectal cancer
CONCLUSIONS: Co-occurring RAS/RAF alterations define a unique subtype of ERBB2 amplified CRC that has increased intratumoral heterogeneity, interlesional discordance and resistance to trastuzumab-based combinations. Further examination of trastuzumab deruxtecan in this previously understudied cohort of ERBB2 amplified CRC is warranted.PMID:38345769 | DOI:10.1158/1078-0432.CCR-23-2581 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 12, 2024 Category: Cancer & Oncology Authors: Harshabad Singh Pranshu Sahgal Kevin Kapner Steven M Corsello Hersh Gupta Rahul Gujrathi Yvonne Y Li Andrew D Cherniack Raquelle El Alam Joseph Kerfoot Elizabeth Andrews Annette Lee Chetan Nambiar Alison M Hannigan Joshua Remland Lauren Brais Meghan E Lea Source Type: research
Economic evaluation of personalized vs. standard dosing of 5-fluorouracil in first-line chemotherapy for metastatic colorectal cancer in Australia
CONCLUSIONS: PK dose management of 5-FU-based chemotherapy in mCRC patients appears to be a cost-saving strategy in Australia. However, our model estimates are drawn from limited, low-quality evidence. Further evidence from randomized controlled trials (RCTs), directly comparing PK-based to BSA-based dosing across a variety of current regimens, is needed to address our model's uncertainties.PMID:38346317 | DOI:10.1111/bcp.16013 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 12, 2024 Category: Cancer & Oncology Authors: Daniel Erku Jennifer H Martin Michael Michael Peter Galettis Paul Scuffham Source Type: research
Treatment of hepatocellular carcinoma with a portal vein tumor thrombus and pulmonary metastases of rectal cancer with microsatellite stability using atezolizumab plus bevacizumab
Clin J Gastroenterol. 2024 Feb 11. doi: 10.1007/s12328-024-01921-2. Online ahead of print.ABSTRACTHerein, we report the successful treatment using atezolizumab plus bevacizumab of a patient with hepatocellular carcinoma (HCC) with a portal vein tumor thrombus and multiple pulmonary metastases from rectal cancer with microsatellite stability. This patient developed rectal cancer with synchronous pulmonary metastases and HCC. After resecting the primary lesion of the rectal cancer, transcatheter arterial chemoembolization was performed for the HCC. Drug therapy was planned for multiple pulmonary metastases of rectal cancer; ...
Source: Clinical Colorectal Cancer - February 11, 2024 Category: Cancer & Oncology Authors: Yoshitaka Inaba Shohei Chatani Shinichi Murata Yozo Sato Rinpei Imamine Mina Kato Hiroaki Onaya Hidekazu Yamaura Source Type: research
